Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723203 · ClinicalTrials.gov registry record · Phase 2
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
A Phase 2 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00723203 is a Phase 2 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 16 participants.
The verdict
NCT00723203, a Phase 2 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in treating patients with relapsed or refractory acute lymphoblastic leukemia or acute myeloid leukemia.
Interventions
- GENETIC gene expression analysis
- OTHER laboratory biomarker analysis
- DRUG panobinostat
- GENETIC reverse transcriptase-polymerase chain reaction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723203
The ClinicalTrials.gov registry entry for NCT00723203 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which gene expression analysis is the first listed.
NCT00723203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00723203 about?
NCT00723203 is a clinical study titled "Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia". RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in treating patients with relapsed or refractory acute lymphoblastic leukemia or...
What is the current status of trial NCT00723203?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2008-04. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00723203?
The interventions under investigation include: gene expression analysis (GENETIC), laboratory biomarker analysis (OTHER), panobinostat (DRUG), reverse transcriptase-polymerase chain reaction (GENETIC).
Who is sponsoring clinical trial NCT00723203?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.